No AI APIs. Public sources only.
Track biotech catalysts before the market prices them in.
FDA dates, clinical readouts, conferences, SEC filings, and company events in one clean dashboard.
ClinicalTrials.gov, SEC EDGAR, RSS
Change records with old and new values
Supabase, Stripe, Vercel ready
Live workflow
Upcoming catalyst tape
Jun 28
GMAB
Conference update on combination cohorts
Approved/Phase 3ASCO
Jul 10
RVMD
RAS(ON) inhibitor expansion cohort update
Phase 2Phase 2 Readout
Jul 24
ALLO
Cell therapy pipeline investor update
Phase 2Investor Day
Aug 15
RCUS
STAR-221 interim analysis window
Phase 3Phase 3 Readout
Sep 30
EXEL
STELLAR pivotal study top-line data
Phase 3Phase 3 Readout
Oct 1
MRUS
Combination cohort clinical update
Phase 2Phase 2 Readout
Nov 20
NUVL
Potential regulatory action window
RegistrationFDA PDUFA
Dec 15
AVBP
ClinicalTrials.gov primary completion watch
Phase 3Clinical Trial Completion
Investor dashboard
Compact catalyst tracking
| Company | Catalyst | Asset | Phase | Expected | Confidence | Status |
|---|---|---|---|---|---|---|
| GMAB Genmab | Conference update on combination cohorts ASCO | Epcoritamab | Approved/Phase 3 | ASCO 2026 | exact | upcoming |
| RVMD Revolution Medicines | RAS(ON) inhibitor expansion cohort update Phase 2 Readout | RMC-6236 | Phase 2 | July 2026 | month | active |
| ALLO Allogene Therapeutics | Cell therapy pipeline investor update Investor Day | Cema-cel | Phase 2 | July 24, 2026 | exact | upcoming |
| RCUS Arcus Biosciences | STAR-221 interim analysis window Phase 3 Readout | Domvanalimab | Phase 3 | Q3 2026 | quarter | upcoming |
| EXEL Exelixis | STELLAR pivotal study top-line data Phase 3 Readout | Zanzalintinib | Phase 3 | 2H 2026 | half year | upcoming |
Pricing
Scale your watchlist
Free
$0
5 companies
Personal watchlist for early evaluation.
- +Manual catalysts
- +Public dashboard sample data
- +CSV export
Pro
$29
50 companies
For active biotech investors tracking a focused universe.
- +Daily refresh jobs
- +SEC and RSS monitoring
- +Change history
Analyst
$99
250 companies
For analysts and teams managing broad coverage lists.
- +Morning and after-close refresh
- +ClinicalTrials.gov snapshots
- +Priority exports